Article

SEWS procedure a lasting alternative to botulinum toxin

Wilmette, IL-The use of botulinum toxin type A (Botox, Allergan) to remove facial lines is the latest cosmetic procedure craze to hit the national morning programs and evening magazine shows.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image courtesy of New York Eye and Ear Infirmary of Mount Sinai) Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
June 23rd 2025

Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Formosa Pharmaceuticals grants Harrow commercial rights in US to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
June 12th 2025

Formosa Pharmaceuticals grants Harrow commercial rights in US to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia

Q&A: Sunir Garg, MD, shares insights on using chlorhexidine for anti-sepsis
May 29th 2025

Q&A: Sunir Garg, MD, shares insights on using chlorhexidine for anti-sepsis

© 2025 MJH Life Sciences

All rights reserved.